Perpetual Ltd Has $1.79 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Perpetual Ltd grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 4.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,101 shares of the company’s stock after purchasing an additional 541 shares during the period. Perpetual Ltd’s holdings in Neurocrine Biosciences were worth $1,788,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of NBIX. Commerce Bank lifted its position in Neurocrine Biosciences by 2.6% during the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock worth $484,000 after purchasing an additional 108 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Neurocrine Biosciences by 2.7% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company’s stock valued at $496,000 after buying an additional 113 shares in the last quarter. Brooklyn Investment Group lifted its holdings in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 115 shares during the period. Tealwood Asset Management Inc. boosted its position in shares of Neurocrine Biosciences by 1.0% during the 4th quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock worth $1,626,000 after acquiring an additional 118 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Neurocrine Biosciences by 42.0% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock valued at $72,000 after acquiring an additional 157 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Kyle Gano sold 65,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the transaction, the chief executive officer now owns 135,392 shares of the company’s stock, valued at $19,157,968. This trade represents a 32.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the sale, the insider now owns 2,507 shares in the company, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,694 shares of company stock valued at $9,676,730. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Up 1.8 %

NBIX stock opened at $145.88 on Wednesday. The stock’s 50 day simple moving average is $132.17 and its 200 day simple moving average is $131.15. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The stock has a market capitalization of $14.77 billion, a PE ratio of 39.11 and a beta of 0.33.

Analysts Set New Price Targets

Several research firms recently weighed in on NBIX. UBS Group raised their price objective on Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Barclays increased their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 23rd. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Finally, Royal Bank of Canada cut their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $164.81.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.